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A b s t r a c t
A 56-year-old woman, previously healthy, was hospitalized after an episode of ventricular tachycardia in the course of infection. 
In view of the fulminant course of heart failure the patient was connected to an extracorporeal membrane oxygenation (ECMO) sys-
tem. After 3 weeks of treatment with ECMO the patient received a heart transplant. A histopathological examination of the tissues 
of the explanted heart revealed giant cell myocarditis. The patient was treated with immunosuppression based on induction ther-
apy followed by a standard regimen with steroids. Currently, the patient remains in good general condition with an left ventricular 
ejection fraction of 60%.
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Case report
A 56-year-old woman, previously healthy, was hospi-
talized after an episode of ventricular tachycardia (VT) 
in the course of infection manifested by weakness and 
cough. The transthoracic echocardiography (TTE) showed 
reduced left ventricular ejection fraction (LVEF) to 40%. 
Laboratory tests indicated changed parameters of in-
flammation (leukocytosis 12.27 × 103/µl), levels of brain 
natriuretic peptide (NT-proBNP) elevated to 6241 pg/ml, 
and a lower level of potassium (3.2 mmol/l). 
Seventy-two hours after hospitalization, diagnostics 
of acute coronary syndrome due to persistent elevated 
levels of troponin to 0.54 (ng/ml) was performed. Coron-
arography showed no changes in the coronary arteries 
but further reduction of LVEF to 15%. 
The diagnostic algorithm and therapeutic options in 
heart failure were taken into consideration [1]. 
Tachyarrhythmic cardiomyopathy in the course of 
recurrent atrial fibrillation with a  fast (up to 180/min) 
ventricular rate and episodes of non-sustained VT was 
suspected (Figures 1, 2). Because of the ineffectiveness 
of pharmacotherapy, it was decided to perform ablation 
of the AV node preceded by implantation of a  pacing 
system. During the VVI pacemaker implantation proce-
dure there were problems in obtaining proper pacing and 
sensing parameters. Ultimately the septal right ventric-
ular outflow tract was chosen for the endocardial lead 
location.
A day after surgery the patient twice underwent car-
diac arrest in the course of ventricular fibrillation. Grad-
ual deterioration of electrical parameters of cardiac pac-
ing and further reduction of LVEF to 5–10% were noted. 
NT-proBNP increased to 11113  pg/ml with normal lev-
els of procalcitonin and the negative results of tests for 
Lyme disease and enterovirus. In view of the fulminant 
course of heart failure the patient was connected to an 
extracorporeal membrane oxygenation (ECMO) system. 
The biopsy of the right ventricular muscle showed no in-
flammatory lesions [2]. After 3 weeks of treatment with 
ECMO the patient received a heart transplant. A histo-
pathological examination of the tissues of the explanted 
heart revealed giant cell myocarditis with areas of cardio-
myocyte necrosis and formation of fibrous scar limited 
to the walls of the left ventricle and the interventricular 
septum (Figure 3). The patient was treated with immu-
Tomasz Senderek et al. Fulminant HF due to giant cell myocarditis
352 Advances in Interventional Cardiology 2015; 11, 4 (42)
nosuppression based on induction therapy followed by 
a standard regimen with steroids. Currently, the patient 
remains in good general condition with an LVEF of 60%. 
All protocolar biopsies showed no signs of rejection or 
other histological abnormalities including recurrence of 
myocarditis.
Discussion
Giant cell myocarditis is a  rare disease with a  poor 
prognosis [3, 4]. It leads to progressive congestive heart 
failure, with ventricular arrhythmias not treatable by 
pharmacology or ablation. Some patients have symp-
toms resembling acute myocardial infarction or complete 
heart block. The diagnosis is made on the basis of the 
histological image. 
In that case the heart biopsy should be taken earlier, 
although it is not always crucial. Due to a lack of strong 
signs of inflammation or any other reason explaining the 
fulminant course, the wrong diagnosis of tachyarrhyth-
mic cardiomyopathy was made. It was followed by first-
Figure 1. Holter ECG: atrial fibrillation with fast ventricular rate
Figure 2. ECG: arrows show: sinus beats (SR), supraventricular beats (SB), episodes of non-sustained VT (nsVT)
Figure 3. Histopathological examination: specimens 
from the wall of the left ventricle and interventric-
ular septum – image of giant cell (GC) myocarditis 
with areas of fresh and degradable organization 
with the formation of fibrous scar (FS) tissue
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step treatment with implantation of a pacemaker. During 
that surgery electrical parameters in the septum were 
not fully proper because of giant cells in the left ventricle 
and septum. In the case of lack of a left ventricle assist 
device (LVAD) only ECMO before heart transplantation 
can help.
Ninety percent of patients die within a few weeks or 
have a heart transplantation, which is the best chance to 
save the patient’s life. The disease process develops in 
around 30% of grafted hearts and it can be stopped by 
immunosuppressants including steroids.
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